scholarly journals Dance Is an Accessible Physical Activity for People with Parkinson’s Disease

2021 ◽  
Vol 2021 ◽  
pp. 1-20
Author(s):  
Sara Emmanouilidis ◽  
Madeleine E. Hackney ◽  
Susan C Slade ◽  
Hazel Heng ◽  
Dana Jazayeri ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Physical Activity ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Risk Of Bias ◽  
Face To Face ◽  
Gait Quality ◽  
Randomised Controlled ◽  
Digital Delivery

Objective. To evaluate the outcomes of face-to-face, digital, and virtual modes of dancing for people living with Parkinson’s disease (PD). Design. Systematic review informed by Cochrane and PRIMSA guidelines. Data Sources. Seven electronic databases were searched: AMED, Cochrane, PEDro, CINHAL, PsycINFO, EMBASE, and MEDLINE. Methods. Eligible studies were randomised controlled trials (RCT) and other trials with quantitative data. The PEDro scale evaluated risk of bias for RCTs. Joanna Briggs Institute instruments were used to critically appraise non-RCTs. The primary outcome was the feasibility of dance interventions, and the secondary outcomes included gait, balance, quality of life, and disability. Results. The search yielded 8,327 articles after duplicates were removed and 38 met the inclusion criteria. Seven were at high risk of bias, 20 had moderate risk of bias, and 11 had low risk of bias. There was moderately strong evidence that dance therapy was beneficial for balance, gait, quality of life, and disability. There was good adherence to digital delivery of dance interventions and, for people with PD, online dance was easy to access. Conclusion. Dancing is an accessible form of exercise that can benefit mobility and quality of life in people with PD. The COVID-19 pandemic and this review have drawn attention to the benefits of access to digital modes of physical activity for people living with chronic neurological conditions.

scholarly journals Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson’s disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Sarah Scobie ◽  
Sue Jowett ◽  
Tosin Lambe ◽  
Smitaa Patel ◽  
Rebecca Woolley ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
Language Therapy ◽  
Voice Treatment ◽  
Cost Consequence ◽  
Randomised Controlled

Abstract Background The PD COMM pilot randomised controlled trial compared Lee Silverman Voice Treatment (LSVT® LOUD) with standard NHS speech and language therapy (SLT) and a control arm in people with Parkinson’s disease (PwPD) with self-reported problems with voice or speech. This analysis compares costs and quality of life outcomes between the trial arms, and considers the validity of the alternative outcome measures for economic evaluations. Methods A comparison of costs and outcomes was undertaken alongside the PD COMM pilot trial involving three arms: LSVT® LOUD treatment (n = 30); standard NHS SLT (n = 30); and a control arm (n = 29) excluded from receiving therapy for at least 6 months after randomisation unless deemed medically necessary. For all trial arms, resource use and NHS, social care and patient costs and quality of life were collected prospectively at baseline, 3, 6, and 12 months. Total economic costs and outcomes (EQ-5D-3L, ICECAP-O) were considered over the 12-month follow-up period from an NHS payer perspective. Quality of life measures for economic evaluation of SLT for people with Parkinson’s disease were compared. Results Whilst there was no difference between arms in voice or quality of life outcomes at 12 months, there were indications of differences at 3 months in favour of SLT, which need to be confirmed in the main trial. The estimated mean cost of NHS care was £3288 per patient per year for the LSVT® LOUD arm, £2033 for NHS SLT, and £1788 for the control arm. EQ-5D-3L was more strongly correlated to voice impairment than ICECAP-O, and was sensitive to differences in voice impairment between arms. Conclusions The pilot did not identify an effect of SLT on disease-specific or economic outcomes for PwPD at 12 months; however, there appeared to be improvements at 3 months. In addition to the sample size not powered to detect difference in cost-consequence analysis, many patients in the control arm started SLT during the 12-month period used for economic analysis, in line with the study protocol. The LSVT® LOUD intervention was more intense and therefore more costly. Early indications suggest that the preferred economic outcome measure for the full trial is EQ-5D-3L; however, the ICECAP-O should still be included to capture a broader measure of wellbeing. Trial registration International Standard Randomised Controlled Trial Number Register: ISRCTN75223808. Registered 22 March 2012.

Effects of water-based exercise on functioning and quality of life in people with Parkinson’s disease: a systematic review and meta-analysis

2020 ◽  
Vol 34 (12) ◽  
pp. 1425-1435
Author(s):  
Mansueto Gomes Neto ◽  
Sarah Souza Pontes ◽  
Lorena de Oliveira Almeida ◽  
Cássio Magalhães da Silva ◽  
Cristiano da Conceição Sena ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Usual Care ◽  
Fear Of Falling ◽  
Functional Performance ◽  
Controlled Trials ◽  
Water Based ◽  
Randomised Controlled

Aim: To investigate the effects of the water-based exercise on balance, mobility, mobility and functional independence, functional performance, fear of falling and quality of life in people with Parkinson’s disease. Methods: We searched pubmed/MEDLINE, Cochrane Central Register of Controlled Trials, PEDro data base and SciELO to June 2020 for randomised controlled trials that investigated the effects of water-based exercise in people with Parkinson’s disease. Two comparisons were made: water-based exercise versus usual care and water-based exercise versus land-exercise. The main outcomes were Balance, Confidence, Mobility, Unified Parkinson’s Disease Rating Scale and quality of life. Mean differences (MD) with 95% confidence interval (CI) were calculated, and heterogeneity was assessed using the I2 test. Results: Fifteen randomised controlled trials were found (435 people). Compared to usual care, water-based exercise resulted in improvement in balance MD (9.1, 95% CI: 6.5, 11.8, N = 45). Water-based exercise resulted in improvement in balance MD (3.1, 95% CI: 1.2, 5.0, N = 179), mobility MD (−2.2, 95% CI: −3.3, −1.0, N = 197) and quality of life MD (−5.5, 95% CI: −11, −0.07, N = 98) compared to land-based exercise, but without significant difference in functional performance MD (0.01, 95% CI: −2.6 to 2.7, N = 69). Land-based exercise resulted in improvement in fear of falling MD (−3.5, 95% CI: −5.6, −1.3, N = 58) compared to water-based exercise. Conclusion: Water-based exercise was more efficient than land-based exercise and/or usual care in improving balance, mobility and quality of life in people with Parkinson’s disease.

scholarly journals Physical activity benefits the elderly with Parkinson’s disease

2020 ◽  
Vol 30 (Supplement_5) ◽  
Author(s):  
S Lee
Keyword(s):  
Quality Of Life ◽  
Physical Activity ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Physical Activity Intervention ◽  
The Elderly ◽  
Negative Effect ◽  
Effect Of Pd

Abstract Background Growing number of ageing population adds to the increase in the number of the patients with Parkinson's disease (PD). PD is an idiopathic and progressive disease that significantly affects patients' daily activities and quality of life. The current study sought to explore the role of physical activity as correlates of coping strategies for the elderly with PD. Methods We employed a four-year follow-up study design using data drawn from the Survey of Health Ageing and Retirement in Europe (SHARE) - waves 4 and 6. A total of 421 who ever diagnosed or currently having PD (Wave 4) were followed-up (Wave 6). Cross-lagged associations were examined between self-rated health, limits of daily activities, psychological distress, CASP - quality of life scale (Control, Autonomy, Self-realization, Pleasure), and life satisfaction. A path model was developed to examine if moderate to vigorous physical activities mitigated negative effect of PD. Results ANOVA showed that well-being index in the older adults with PD decreased at follow-up point across the measured variables, self-rated health (p < .001), limits of daily activity (p < .001), depression (p < .001), loneliness (p < .001), CASP (p < .001) and life satisfaction (p < .001) after controlling for socio-demographic and other health variables. Moderate to vigorous level of physical activity appeared to significantly mitigate the negative effect of PD. Conclusions In order to improve the quality of life among the elderly with PD, multilayer intervention should be coupled with the medical treatment. Public health should design and implement enduring rehabilitation program and adaptive physical activity intervention that help psychological and behavioral adaptation process to chronic illness for Parkinson patients. Mobility assistance services or home care products can relieve the difficulties to perform activities of daily living of the elderly with Parkinson's disease. Key messages Parkinson patients are more likely to experience difficulties to perform activities of daily living. Physical activity intervention can enhance living of the elderly with Parkinson’s disease.

scholarly journals Virtual games and quality of life in Parkinson’s disease: A randomised controlled trial

2013 ◽  
Vol 02 (04) ◽  
pp. 97-101 ◽  
Author(s):  
Glicia Pedreira ◽  
Antonio Prazeres ◽  
Danilo Cruz ◽  
Irênio Gomes ◽  
Larissa Monteiro ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
Randomised Controlled

scholarly journals Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson’s disease: a large pragmatic randomised controlled trial (PD REHAB)

2016 ◽  
Vol 20 (63) ◽  
pp. 1-96 ◽  
Author(s):  
Carl E Clarke ◽  
Smitaa Patel ◽  
Natalie Ives ◽  
Caroline E Rick ◽  
Rebecca Woolley ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cost Effectiveness ◽  
Adverse Events ◽  
Controlled Trial ◽  
Clinical Effectiveness ◽  
Randomised Controlled ◽  
The Uk

BackgroundCochrane reviews of physiotherapy (PT) and occupational therapy (OT) for Parkinson’s disease found insufficient evidence of effectiveness, but previous trials were methodologically flawed with small sample size and short-term follow-up.ObjectivesTo evaluate the clinical effectiveness and cost-effectiveness of individualised PT and OT in Parkinson’s disease.DesignLarge pragmatic randomised controlled trial.SettingThirty-eight neurology and geriatric medicine outpatient clinics in the UK.ParticipantsSeven hundred and sixty-two patients with mild to moderate Parkinson’s disease reporting limitations in activities of daily living (ADL).InterventionPatients were randomised online to either both PT and OT NHS services (n = 381) or no therapy (n = 381). Therapy incorporated a patient-centred approach with individual assessment and goal setting.Main outcome measuresThe primary outcome was instrumental ADL measured by the patient-completed Nottingham Extended Activities of Daily Living (NEADL) scale at 3 months after randomisation. Secondary outcomes were health-related quality of life [Parkinson’s Disease Questionnaire-39 (PDQ-39); European Quality of Life-5 Dimensions (EQ-5D)], adverse events, resource use and carer quality of life (Short Form questionnaire-12 items). Outcomes were assessed before randomisation and at 3, 9 and 15 months after randomisation.ResultsData from 92% of the participants in each group were available at the primary time point of 3 months, but there was no difference in NEADL total score [difference 0.5 points, 95% confidence interval (CI) –0.7 to 1.7;p = 0.4] or PDQ-39 summary index (0.007 points, 95% CI –1.5 to 1.5;p = 1.0) between groups. The EQ-5D quotient was of borderline significance in favour of therapy (–0.03, 95% CI –0.07 to –0.002;p = 0.04). Contact time with therapists was for a median of four visits of 58 minutes each over 8 weeks (mean dose 232 minutes). Repeated measures analysis including all time points showed no difference in NEADL total score, but PDQ-39 summary index (curves diverging at 1.6 points per annum, 95% CI 0.47 to 2.62;p = 0.005) and EQ-5D quotient (0.02, 95% CI 0.00007 to 0.03;p = 0.04) showed significant but small differences in favour of the therapy arm. Cost-effective analysis showed that therapy was associated with a slight but not significant gain in quality-adjusted life-years (0.027, 95% CI –0.010 to 0.065) at a small incremental cost (£164, 95% CI –£141 to £468), resulting in an incremental cost-effectiveness ratio of under £4000 (£3493, 95% –£169,371 to £176,358). There was no difference in adverse events or serious adverse events.ConclusionsNHS PT and OT did not produce immediate or long-term clinically meaningful improvements in ADL or quality of life in patients with mild to moderate Parkinson’s disease. This evidence does not support the use of low-dose, patient-centred, goal-directed PT and OT in patients in the early stages of Parkinson’s disease. Future research should include the development and testing of more structured and intensive PT and OT programmes in patients with all stages of Parkinson’s disease.Trial registrationCurrent Controlled Trials ISRCTN17452402.FundingThis project was funded by the NIHR Health Technology Assessment programme and will be published in full inHealth Technology Assessment; Vol. 20, No. 63. See the NIHR Journals Library website for further project information. The Birmingham Clinical Trials Unit, University of Birmingham, received support from the UK Department of Health up to March 2012. Catherine Sackley was supported by a NIHR senior investigator award, Collaboration for Leadership in Applied Health Research and Care East of England and West Midlands Strategic Health Authority Clinical Academic Training award.

scholarly journals Stimulation of the tibial nerve: a protocol for a multicentred randomised controlled trial for urinary problems associated with Parkinson’s disease—STARTUP

BMJ Open ◽  
2020 ◽  
Vol 10 (2) ◽  
pp. e034887 ◽  
Author(s):  
Doreen McClurg ◽  
Jalesh Panicker ◽  
Richard W Walker ◽  
AnneLouise Cunnington ◽  
Katherine H O Deane ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
International Prostate Symptom Score ◽  
Bladder Dysfunction ◽  
Tibial Nerve ◽  
Short Form ◽  
Controlled Trial ◽  
Randomised Controlled

IntroductionParkinson’s disease is the second most common chronic neurodegenerative condition with bladder dysfunction affecting up to 71%. Symptoms affect quality of life and include urgency, frequency, hesitancy, nocturia and incontinence. Addressing urinary dysfunction is one of the top 10 priority research areas identified by the James Lind Alliance and Parkinson’s UK.ObjectivesConduct a randomised controlled trial (RCT) targeting people with Parkinson’s disease (PwP) who have self-reported problematic lower urinary tract symptoms, investigating the effectiveness of transcutaneous tibial nerve stimulation (TTNS) compared with sham TTNS. Implement a standardised training approach and package for the correct application of TTNS. Conduct a cost-effectiveness analysis of TTNS compared with sham TTNS.Methods and analysisAn RCT of 6 weeks with twice weekly TTNS or sham TTNS. Participants will be recruited in 12 National Health Service neurology/movement disorder services, using a web-based randomisation system, and will be shown how to apply TTNS or sham TTNS. Participants will receive a weekly telephone call from the researchers during the intervention period. The trial has two coprimary outcome measures: International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form and the International Prostate Symptom Score. Secondary outcomes include a 3-day bladder diary, quality of life, acceptability and fidelity and health economic evaluation. Outcomes will be measured at 0, 6 and 12 weeks.A sample size of 208 randomised in equal numbers to the two arms will provide 90% power to detect a clinically important difference of 2.52 points on the Internatioanl Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF) and of 3 points in the International Prostate Symptom Score total score at 12 weeks at 5% significance level, based on an SD of 4.7 in each arm and 20% attrition at 6 weeks. Analysis will be by intention to treat and pre defined in a statistical analysis planEthics and disseminationEast of Scotland Research Ethics Service (EoSRES), 18/ES00042, obtained on 10 May 2018. The trial will allow us to determine effectiveness, safety, cost and acceptability of TTNS for bladder dysfunction in PWP. Results will be published in open access journals; lay reports will be posted to all participants and presented at conferences.Trial registration numberISRCTN12437878; Pre-results.

Sign in / Sign up

Export Citation Format

Share Document